Gastroesophageal Reflux Disease Clinical Trial
Official title:
Laryngeal and Esophageal EGF-r Expression in Patients With Reflux Laryngitis
- Saliva plays an important role in the homeostasis of the digestive tract mucosa.
- Salivary organic components, such as the Epidermal Growth Factor(EGF) have been found
in defficient concentrations in patients with gastroesophageal reflux disease (GERD)
and reflux related laryngitis (LPR).
- The epidermal growth factor receptor (EGFR) signaling pathway is one of the most
important pathways that regulate growth, survival, proliferation, and differentiation
in mammalian cells
- Eperdermal growth factor receptor (EGFR) overexpression has been linked to
hyperproliferative diseases.
- It is unknown if the inflammatory process in GERD is realated to difficiencies in EGFR
expression.
- The objective of the current study was to try to establish a correlation between the
expression of EGFR in the laryngeal and esophageal mucosa and the severity of
laryngitis in adults with GERD and LPR
Objectives: The expression of the Epidermal Growth Factor receptor (EGFR) has been studied in a number of neoplastic and chronic diseases, but there are no reports in literature regarding its expression in chronic laryngitis associated to Gastroesophageal Reflux isease (GERD), also known as Laryngopharyngeal Reflux (LPR). The current study compared the expression of EGFR in the esophageal and laryngeal mucosa of adults with GERD and LPR. Study Design: Prospective based on imunohistochemical analysis of parafine embedded biopsy specimens and clinical data. Methods: From August, 2004 to February 2007 a total of 24 adults with confirmed diagnosis of LPR and no other clinical conditions or habits known to cause chronic laryngitis were studied at a University Hospital. Biopsies of the distal esophagus and the retrocrycoid laryngeal mucosa were obtained during upper digestive endoscopy. Data were analyzed statistically comparing samples in each individual and between individuals using the severity of histological signs of inflammation on hematoxacillin and eosinophillin (HE) stains to immunohistochemical analysis of the expression of EGFR. Other independent variables were severity of symptoms and signs, gender and age. Fishers´s exact test and multivariance ANOVA tests were used with significance level established at 95%. ;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02135107 -
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
|
Phase 3 | |
| Completed |
NCT01432392 -
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
|
N/A | |
| Recruiting |
NCT01249482 -
Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
|
N/A | |
| Completed |
NCT01200550 -
The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients
|
N/A | |
| Completed |
NCT01578642 -
Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease
|
Phase 2 | |
| Completed |
NCT00998244 -
Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease
|
N/A | |
| Unknown status |
NCT01128608 -
The Effect of High PCO2 Solution on Esophageal Acid Sensation
|
N/A | |
| Completed |
NCT00978016 -
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
|
Phase 2 | |
| Completed |
NCT00768443 -
Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
|
N/A | |
| Completed |
NCT00768196 -
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients
|
N/A | |
| Recruiting |
NCT00498082 -
Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease
|
N/A | |
| Completed |
NCT00886197 -
Diagnostic Efficacy of Narrow Band Imaging in Patients With Gastroesophageal Reflux Disease
|
N/A | |
| Completed |
NCT00378898 -
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
|
N/A | |
| Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
| Completed |
NCT00507377 -
Foreshortened Esophagus and Its Surgical Therapy
|
||
| Completed |
NCT00165022 -
Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population
|
N/A | |
| Completed |
NCT00214552 -
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
|
Phase 3 | |
| Completed |
NCT00625495 -
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
| Completed |
NCT00618150 -
Patient Education in Gastroesophageal Reflux Disease
|
N/A | |
| Completed |
NCT03299985 -
Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease
|
N/A |